TITLE

Spontaneous dyskinesia in first episode schizophrenia

AUTHOR(S)
Puri, B. K.; Barnes, Thomas R. E.; Chapman, M. J.; Hutton, S. B.; Joyce, Eileen M.
PUB. DATE
January 1999
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jan1999, p76
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66699686

 

Related Articles

  • Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Fenton, Wayne S.; Blyler, Crystal R.; Wyatt, Richard J.; McGlashan, Thomas H. // British Journal of Psychiatry;Sep97, Vol. 171, p265 

    Background Although movement disorders have been noted among patients never exposed to neuroleptic medications, the specificity of spontaneous dyskinesia to schizophrenia has rarely been examined. Method By abstracting detailed case records, we compared the prevalence of dyskinetic movements...

  • Social functioning in first- and multiepisode schizophrenia. Grant, Christina; Addington, Jean; Addington, Donald; Konnert, Candace; Grant, C; Addington, J; Addington, D; Konnert, C // Canadian Journal of Psychiatry;Oct2001, Vol. 46 Issue 8, p746 

    Objective: To compare the social functioning of individuals experiencing their first episodes of schizophrenia with those who have experienced multiple episodes and with nonpsychiatrically ill control subjects.Method: Subjects included 40 patients with first-episode...

  • Disease-relevant autoantibodies in first episode schizophrenia. Zandi, Michael S.; Irani, Sarosh R.; Lang, Bethan; Waters, Patrick; Jones, Peter B.; McKenna, Peter; Coles, Alasdair J.; Vincent, Angela; Lennox, Belinda R. // Journal of Neurology;Apr2011, Vol. 258 Issue 4, p686 

    A letter to the editor is presented on N-methyl-D-aspartate receptor (NMDAR) antibody for the first episode of the disorder schizophrenia.

  • The Northwick Park Study of First Episodes of Schizophrenia. Grahame, Peter S. // British Journal of Psychiatry;Sep86, Vol. 149, p382 

    A letter to the editor is presented in response to the article regarding the Northwick Park study of first episodes of schizophrenia published in the February 1986 issue.

  • Drs Johnstone, Macmillan and Crow Reply. Johnstone, Eve C.; MacMillan, J. Fiona; Crow, T. J. // British Journal of Psychiatry;Sep86, Vol. 149, p383 

    A reply to a letter to the editor is presented in response to the article regarding the study on the first episodes of schizophrenia published in the previous issue.

  • First episode schizophrenia: predicting outcome. Muijen, Matthijs // British Journal of Psychiatry;May91, Vol. 158, p713 

    A letter to the editor is presented in response to an article about prediction of outcome following first episode of schizophrenia in the August 1990 issue.

  • First-Episode Schizophrenia: A Focus on Pharmacological Treatment and Safety Considerations. Kelly, Deanna L.; Conley, Robert R.; Carpenter, William T. // Drugs;2005, Vol. 65 Issue 8, p1113 

    Schizophrenia is a debilitating disorder, which is usually chronic, and is one of the most devastating medical illnesses. Early and appropriate treatment with antipsychotics is an important strategy for patients with first-episode schizophrenia. However, there are many possible safety issues for...

  • CITATIONS AND CLINICIANS' NOTES: SCHIZOPHRENIA.  // Current Medical Literature: Psychiatry;2004, Vol. 15 Issue 3, p71 

    Provides information on several studies on schizophrenia. General and specific cognitive deficits in schizophrenia; Trial on the use of cognitive therapy for command hallucinations; Improvement in severe, chronic schizophrenia and its neuropsychological correlates; Prediction of acute treatment...

  • Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. Bedard, P.; Parkes, J.D.; Marsden, C.D. // British Medical Journal;4/15/1978, Vol. 1 Issue 6118, p954 

    Studies the effect of oxiperomide, a dopamine-receptor antagonist, on drug-induced dyskinesias in patients with Parkinson's disease and on spontaneous dyskinesias. Decrease in dyskinesias in Parkinson's disease patients; Reduction of the intensity of spontaneous dyskinesias in patients with...

  • The Chinese First-Episode Schizophrenia Trial: Background and Study Design. Han, X.; Yuan, Y. B.; Yu, X.; Zhao, J. P.; Wang, C. Y.; Lu, Z.; Yang, F. D.; Dong, H.; Wu, Y. F.; Ungvari, G. S.; Xiang, Y. T.; Chiu, H. F. K. // East Asian Archives of Psychiatry;Dec2014, Vol. 24 Issue 4, p169 

    Schizophrenia is a complex illness with unknown aetiology and pathogenesis. Currently, a considerable number of patients with schizophrenia do not receive standardised and systematic treatment in China. In the past years, many controlled trials have been conducted in chronic schizophrenia. In...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics